Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-κB-driven inflammation and cardiovascular risk.
Aging
/ genetics
Cardiovascular Diseases
/ genetics
Cellular Senescence
/ genetics
Child, Preschool
Depressive Disorder, Major
/ genetics
Epigenesis, Genetic
/ genetics
Female
Genome-Wide Association Study
/ methods
Humans
Inflammation
/ genetics
Male
NF-kappa B
/ genetics
Risk Factors
Signal Transduction
/ genetics
Stress, Psychological
/ genetics
Tacrolimus Binding Proteins
/ genetics
Up-Regulation
/ genetics
FKBP5
aging
epigenetics
inflammation
psychosocial stress
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
04 06 2019
04 06 2019
Historique:
pubmed:
23
5
2019
medline:
24
3
2020
entrez:
23
5
2019
Statut:
ppublish
Résumé
Aging and psychosocial stress are associated with increased inflammation and disease risk, but the underlying molecular mechanisms are unclear. Because both aging and stress are also associated with lasting epigenetic changes, a plausible hypothesis is that stress along the lifespan could confer disease risk through epigenetic effects on molecules involved in inflammatory processes. Here, by combining large-scale analyses in human cohorts with experiments in cells, we report that FKBP5, a protein implicated in stress physiology, contributes to these relations. Across independent human cohorts (total
Identifiants
pubmed: 31113877
pii: 1816847116
doi: 10.1073/pnas.1816847116
pmc: PMC6561294
doi:
Substances chimiques
NF-kappa B
0
Tacrolimus Binding Proteins
EC 5.2.1.-
tacrolimus binding protein 5
EC 5.2.1.8
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11370-11379Subventions
Organisme : NIMH NIH HHS
ID : U19 MH069056
Pays : United States
Informations de copyright
Copyright © 2019 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Conflict of interest statement: E.B.B. receives a research grant from Böhringer-Ingelheim to develop cellular and animal models of enhanced FKBP5 function. She is also coinventor on the following patent application: “FKBP5: a novel target for antidepressant therapy” (European Patent no. EP 1687443 B1).
Références
EMBO J. 2001 Apr 17;20(8):1974-83
pubmed: 11296230
Mol Cell Biol. 2002 Oct;22(19):6689-96
pubmed: 12215526
JAMA. 2003 Jul 9;290(2):215-21
pubmed: 12851276
Nat Cell Biol. 2004 Feb;6(2):97-105
pubmed: 14743216
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1503-8
pubmed: 15178568
Eur J Cancer. 2004 Dec;40(18):2829-36
pubmed: 15571967
Eur Heart J. 2005 Dec;26(23):2537-42
pubmed: 16126719
J Biol Chem. 2006 Feb 3;281(5):2405-13
pubmed: 16303768
BMJ. 2006 Mar 4;332(7540):521-5
pubmed: 16428252
Psychol Med. 2006 Jun;36(6):797-805
pubmed: 16623962
Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1319-24
pubmed: 17229839
Epigenetics. 2006 Jul-Sep;1(3):127-30
pubmed: 17965610
Arch Gen Psychiatry. 2008 Apr;65(4):409-15
pubmed: 18391129
Arch Pediatr Adolesc Med. 2009 Dec;163(12):1135-43
pubmed: 19996051
Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034
pubmed: 20066092
J Neurosci. 2010 Jan 13;30(2):591-9
pubmed: 20071522
Endocrinology. 2010 Sep;151(9):4332-43
pubmed: 20668026
PLoS One. 2011 Feb 25;6(2):e17490
pubmed: 21364760
Mol Psychiatry. 2011 Jul;16(7):738-50
pubmed: 21483429
Psychopharmacology (Berl). 2011 Nov;218(1):303-12
pubmed: 21509501
Physiol Behav. 2012 Apr 12;106(1):29-39
pubmed: 21888923
Neuropsychopharmacology. 2012 May;37(6):1455-64
pubmed: 22237309
Nat Methods. 2012 Feb 28;9(3):215-6
pubmed: 22373907
J Immunol. 2012 May 1;188(9):4226-34
pubmed: 22474024
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10522-7
pubmed: 22689993
Curr Biol. 2012 Sep 11;22(17):R741-52
pubmed: 22975005
Nat Neurosci. 2013 Jan;16(1):33-41
pubmed: 23201972
Expert Rev Cardiovasc Ther. 2013 Jan;11(1):55-9
pubmed: 23259445
Mol Cell. 2013 Mar 7;49(5):825-37
pubmed: 23473601
Curr Protoc Stem Cell Biol. 2013 May;Chapter 1:Unit 1B.10
pubmed: 23661244
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
J Am Coll Cardiol. 2013 Sep 10;62(11):970-8
pubmed: 23810885
J Clin Invest. 2013 Oct;123(10):4158-69
pubmed: 23999428
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Genome Biol. 2014 Feb 04;15(2):R31
pubmed: 24495553
Atherosclerosis. 2014 May;234(1):206-13
pubmed: 24681815
Circ Res. 2014 Jun 6;114(12):1867-79
pubmed: 24902971
J Biol Chem. 2014 Sep 19;289(38):26263-76
pubmed: 25104352
Nat Chem Biol. 2015 Jan;11(1):33-7
pubmed: 25436518
J Mol Cell Cardiol. 2015 Jun;83:122-30
pubmed: 25510678
Br J Cancer. 2015 May 26;112(11):1772-81
pubmed: 25942396
Nucleic Acids Res. 2015 Aug 18;43(14):6983-93
pubmed: 26101251
Epigenetics Chromatin. 2015 Jun 23;8:22
pubmed: 26113876
Neuropsychopharmacology. 2016 Jan;41(1):261-74
pubmed: 26250598
Atherosclerosis. 2015 Oct;242(2):589-94
pubmed: 26318109
Biol Psychiatry. 2016 Sep 1;80(5):372-80
pubmed: 26410355
Genome Biol. 2015 Dec 17;16:266
pubmed: 26673150
Scand J Immunol. 2016 Apr;83(4):255-66
pubmed: 26808160
Sci Transl Med. 2016 Feb 10;8(325):325ra19
pubmed: 26865567
Mol Cell. 2016 Apr 21;62(2):157-168
pubmed: 27105112
Mol Psychiatry. 2017 May;22(5):640-646
pubmed: 28289275
Curr Cardiol Rep. 2017 Sep 20;19(11):111
pubmed: 28932967
Nat Rev Genet. 2018 Jun;19(6):371-384
pubmed: 29643443
Epigenetics Chromatin. 2018 Jul 4;11(1):39
pubmed: 29973294
Mol Cell Biol. 1995 Aug;15(8):4395-402
pubmed: 7542743
J Leukoc Biol. 1994 Nov;56(5):559-64
pubmed: 7964163
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3792-7
pubmed: 9520446
Am J Prev Med. 1998 May;14(4):245-58
pubmed: 9635069